Breaking News, Collaborations & Alliances

Fortress Biotech Forms New Subsidiary

Caelum Biosciences together with Columbia Univ. to develop novel treatment for AL amyloidosis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fortress Biotech has formed a new subsidiary company, Caelum Biosciences, to advance the development of CAEL-101 (11-1F4) for the treatment of amyloid light chain (AL) amyloidosis. Caelum has entered into an agreement with Columbia University to secure exclusive worldwide license rights to CAEL-101, a chimeric fibril-reactive monoclonal antibody (mAb) currently being evaluated in a Phase 1a/1b study. In addition, Fortress announced the appointment of Michael Spector as Caelum’s chief executive o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters